NCT00615108已完成不适用
Safety and Effectiveness of Micardis Tablets Taken Once Daily at 40 mg/Day and 80 mg/Day in Hypertension Patients
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,148
- 试验地点
- 8
- 主要终点
- Percentage of Patients Achieving Blood Pressure (BP) Control
研究概览
简要总结
The purpose of this observational study is to survey the safety and effectiveness of the product under the real condition of usual practice in Taiwanese hypertensive patients. During the 8-week observation, the safety profiles and the clinical evaluation in between doses through blood pressure (BP) measurement for overall effectiveness of telmisartan therapy will be concluded.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female.
- •Aged 20 to 80 years old.
- •Patients meet one of following two criteria:
- •Adult essential hypertensive either newly diagnosed and untreated, or previously treated and uncontrolled patients; sitting blood pressure: systolic blood pressure (BP) > 140 mmHg but < 180 mmHg, and/or diastolic BP > 90 mmHg but < 110 mmHg).
- •Patients who are assessed to benefit from the intake of angiotensin II receptor blocker (ARB) monotherapy or as add-on medication.
排除标准
- •Patients with contraindications to telmisartan use (as per the Micardis® Tablets package insert).
- •Known hypersensitivity to the active ingredient or to any of the excipients of Micardis® Tablets.
- •Any other clinical condition which, in the opinion of the attending physician, would not allow safe administration of the study medications.
结局指标
主要结局
Percentage of Patients Achieving Blood Pressure (BP) Control
时间窗: 01-Dec-2006 to 31-Dec-2008
BP control was defined as diastolic blood pressure/systolic blood pressure DBP/SBP\< 90/140 mm-Hg during observation period. BP is measured every four weeks. The observation period is 8 weeks.
次要结局
- Percentage of Patients Achieving BP Response(01-Dec-2006 to 31-Dec-2008)
- Overall Assessment by Attending Physicians(01-Dec-2006 to 31-Dec-2008)
- Overall Assessment by Patients(01-Dec-2006 to 31-Dec-2008)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
不适用
Post-Marketing Surveillance of Micardis® (Telmisartan) in Patients With HypertensionHypertensionNCT02242838Boehringer Ingelheim6,336
已完成
不适用
Safety, Tolerability and Efficacy of Micardis® in Patients With Essential HypertensionHypertensionNCT02176850Boehringer Ingelheim19,870
已完成
不适用
Post Marketing Surveillance (PMS) Study to Assess Safety and Efficacy of Micardis in Patients With Essential HypertensionHypertensionNCT02245464Boehringer Ingelheim13,066
已完成
不适用
Micardis® in Patients With Essential HypertensionHypertensionNCT02187705Boehringer Ingelheim1,688
已完成
不适用
Observation of Therapy With Micardis® (Telmisartan) in Patients With Essential Hypertension in HospitalsHypertensionNCT02238262Boehringer Ingelheim2,318